Overview
- The Journal of the American Heart Association published a OneFlorida+ analysis that matched 13,204 GLP‑1 receptor agonist users to 13,204 nonusers and found lower hazards for several outcomes.
- GLP‑1 use was associated with a 13% lower hazard of stroke/TIA, 31% lower hazard of pulmonary embolism, 17% lower hazard of venous thromboembolism, 21% fewer emergency department visits, and a 44% lower all‑cause mortality rate.
- The study analyzed 26,408 adults with obesity and at least one autoimmune disease drawn from OneFlorida+ records spanning 2014–2024 and used time‑dependent propensity matching to emulate a randomized trial.
- Authors and external experts caution that the results are observational and vulnerable to residual confounding, coding errors, uncertain medication adherence, and selection biases that prevent firm causal claims.
- Reported at the ADA Scientific Sessions on June 6, 2026, the findings add to growing real‑world signals of benefits beyond weight loss and glucose control and have prompted calls for prospective randomized trials to guide care for this high‑risk group.